表紙
市場調査レポート

ContraFect Corporationの製品パイプライン分析

ContraFect Corporation - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 253751
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
ContraFect Corporationの製品パイプライン分析 ContraFect Corporation - Product Pipeline Review - 2015
出版日: 2015年09月09日 ページ情報: 英文 38 Pages
概要

ContraFect Corporationは、米国のバイオテクノロジー企業であり、悪性および薬剤耐性をもつ微生物を死滅させる技術や治療薬、製品を開発しており、治療薬には薬剤耐性ブドウ菌やインフルエンザ、グラム陽性菌を原因とする感染症に対する薬剤などがあります。

当レポートでは、ContraFect Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

ContraFect Corporationの基本情報

  • ContraFect Corporationの概要
  • 主要情報
  • 企業情報

ContraFect Corporation:R&Dの概要

  • 主な治療範囲

ContraFect Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

ContraFect Corporation:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

ContraFect Corporation:薬剤プロファイル

  • CF-301
  • CF-401
  • CF-402
  • CF-403
  • CF-404
  • Monoclonal Antibody 1 for Influenza
  • CF-302
  • CF-303
  • CF-304
  • CF-305
  • CF-306
  • CF-307
  • CF-308
  • CF-309
  • Monoclonal Antibodies for Influenza

ContraFect Corporation:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

ContraFect Corporation:最新のパイプライン情報

ContraFect Corporation:開発休止中のプロジェクト

ContraFect Corporation:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07551CDB

Summary

Global Markets Direct's, 'ContraFect Corporation - Product Pipeline Review - 2015' , provides an overview of the ContraFect Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ContraFect Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ContraFect Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ContraFect Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ContraFect Corporation's pipeline products

Reasons to buy

  • Evaluate ContraFect Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ContraFect Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ContraFect Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ContraFect Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ContraFect Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ContraFect Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ContraFect Corporation Snapshot
    • ContraFect Corporation Overview
    • Key Information
    • Key Facts
  • ContraFect Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • ContraFect Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ContraFect Corporation - Pipeline Products Glance
    • ContraFect Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • ContraFect Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ContraFect Corporation - Drug Profiles
    • CF-301
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-403
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-404
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Influenza
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-302
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-303
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-304
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-305
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-306
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-307
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-308
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CF-309
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ContraFect Corporation - Pipeline Analysis
    • ContraFect Corporation - Pipeline Products by Target
    • ContraFect Corporation - Pipeline Products by Route of Administration
    • ContraFect Corporation - Pipeline Products by Molecule Type
    • ContraFect Corporation - Pipeline Products by Mechanism of Action
  • ContraFect Corporation - Recent Pipeline Updates
  • ContraFect Corporation - Dormant Projects
  • ContraFect Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ContraFect Corporation, Key Information
  • ContraFect Corporation, Key Facts
  • ContraFect Corporation - Pipeline by Indication, 2015
  • ContraFect Corporation - Pipeline by Stage of Development, 2015
  • ContraFect Corporation - Monotherapy Products in Pipeline, 2015
  • ContraFect Corporation - Phase I, 2015
  • ContraFect Corporation - Preclinical, 2015
  • ContraFect Corporation - Discovery, 2015
  • ContraFect Corporation - Pipeline by Target, 2015
  • ContraFect Corporation - Pipeline by Route of Administration, 2015
  • ContraFect Corporation - Pipeline by Molecule Type, 2015
  • ContraFect Corporation - Pipeline Products by Mechanism of Action, 2015
  • ContraFect Corporation - Recent Pipeline Updates, 2015
  • ContraFect Corporation - Dormant Developmental Projects,2015

List of Figures

  • ContraFect Corporation - Pipeline by Top 10 Indication, 2015
  • ContraFect Corporation - Pipeline by Stage of Development, 2015
  • ContraFect Corporation - Monotherapy Products in Pipeline, 2015
  • ContraFect Corporation - Pipeline by Top 10 Target, 2015
  • ContraFect Corporation - Pipeline by Top 10 Molecule Type, 2015
  • ContraFect Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top